Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 8/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 6/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25147287 | 0.90 | MAP3K12 (0.42) | NOS3NOS1NOS2PRKCERAF1 | |
| SCHEMBL25716154 | 0.84 | PRMT6 (0.39) | NOS3NOS1NOS2PRKCEIDH1 | |
| SCHEMBL13806000 | 0.78 | UHRF1 (0.41) | NOS3NOS1NOS2IDH1PIK3CA | |
| SCHEMBL12173584 | 0.77 | RECQL (0.40) | PRKCEIDH1PIK3CA | |
| SCHEMBL12173583 | 0.77 | PRKCE (0.34) | PRKCEIDH1PIK3CA | |
| SCHEMBL24721128 | 0.75 | FFAR4 (0.39) | PRKCE | |
| SCHEMBL12173580 | 0.75 | MAP3K12 (0.38) | PRKCEIDH1 | |
| SCHEMBL16369764 | 0.75 | IDH1 (0.36) | IDH1PIK3CA | |
| SCHEMBL30731197 | 0.75 | IDH1 (0.34) | IDH1PIK3CARAF1BRAF | |
| SCHEMBL29763355 | 0.75 | IDH1 (0.41) | IDH1RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3309152-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9676759-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | NOS3 3935/4885NOS1 4188/4885NOS2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.